Skip to Content
  • Revenues ($M)$70,074
  • Revenue Percent Change-5.7%
  • Profits ($M)$15,409
  • Profits Percent Change-5.6%
  • Assets ($M)$133,411
  • Employees127,100
  • Market Value — as of March 31, 2016 ($M)$298,563
  • Previous Rank37
  • Morning Consult Brand Index
    A

The 130-year old healthcare conglomerate sells everything from baby shampoo to surgical staples and cancer drugs (it also divested itself of Splenda, the artificial sweetener.) That diversification helped buoy giant J&J in 2015; the company’s strong pharmaceutical sales made up for the less impressive performances of its consumer and medical device divisions. The company’s revenues grew 2.6% in the US, but slid 5.7% worldwide in 2015, largely due to currency fluctuations and the sharp decline in sales of its Hepatitis C drug, Olysio.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Info

CEO
Alex Gorsky
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
New Brunswick, NJ
Websitehttp://www.jnj.com
Years on Fortune 500 List22
Employees127,100

Key Financials (last fiscal year)

$ millions% change
Revenues ($M)$70,074-5.7%
Profits ($M)$15,409-5.6%
Assets ($M)$133,411-
Total Stockholder Equity ($M)$71,150-
Market Value — as of March 31, 2016 ($M)$298,563-

Profit Ratios

Profit as % of Revenues22%
Profits as % of Assets11.6%
Profits as % of Stockholder Equity21.7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)5.48
EPS % Change (from 2014)-3.9%
EPS % Change (5 year annual rate)2.8%
EPS % Change (10 year annual rate)4.7%

Total Return

Total Return to Investors (2015)1.2%
Total Return to Investors (5 year, annualized)14.2%
Total Return to Investors (10 year, annualized)8.8%